Personalized Medicine Decision-Making in a Virtual Clinical Setting

Deep Vein Thrombosis Clinical Trial

Official title: Medical Decision-Making in a Virtual Clinical Setting

Status Completed

Clinical Trial Summary

Background:

-How people respond to drugs depends in part on their genes. For some drugs, doctors can use an individuals genetic background to help in dosing the drug. Researchers want to know how doctors incorporate personalized or genomic medicine into clinical practice.

Objective:

-To study how physicians make personalized treatment decisions

Eligibility:

-Healthy adult primary care physicians who are internal (or family) medicine residents.

Design:

• Participants will complete a screening form.

• Participants will put on a headset, called a head-mounted display, showing a virtual reality environment.

• The environment will contain an exam room and the virtual patient.

• After interacting with the virtual patient, participants will complete a series of survey measures.

• Participation will last for about 60 minutes. The virtual patient interaction and follow-up questions will be audio taped.

Clinical Trial Description

This study will examine factors related to primary care physicians clinical decision-making. Using a virtual clinical interaction experiment, we aim to better understand physicians decision-making processes and to explore their communication behaviors toward patients in the clinical encounter. Physician participants will enter a virtual exam room where they will be asked to respond to a virtual patient, acting as her primary care physician in a follow-up visit to evaluate her for depression. Various aspects of physician communication in the virtual clinic and self-report measures related to decision-making will be analyzed. ;

Related Conditions & MeSH terms

• Blood Clots
• Deep Vein Thrombosis
• Thrombosis
• Venous Thrombosis

• NCT number: NCT02108041
• Study type: Observational
• Source: National Institutes of Health Clinical Center (CC)
• Status: Completed
• Completion date: October 8, 2020